CureVac (NASDAQ:CVAC) Short Interest Update

CureVac (NASDAQ:CVACGet Free Report) was the target of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 4,860,000 shares, an increase of 10.7% from the February 29th total of 4,390,000 shares. Based on an average daily trading volume, of 876,200 shares, the days-to-cover ratio is currently 5.5 days. Approximately 5.3% of the shares of the company are short sold.

CureVac Trading Down 3.4 %

Shares of CVAC stock traded down $0.10 on Tuesday, hitting $2.88. The company had a trading volume of 637,494 shares, compared to its average volume of 793,478. The company has a 50-day moving average price of $3.35 and a 200-day moving average price of $4.64. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.41 and a current ratio of 3.56. CureVac has a twelve month low of $2.76 and a twelve month high of $12.36.

Hedge Funds Weigh In On CureVac

Several institutional investors and hedge funds have recently modified their holdings of the stock. Virtu Financial LLC acquired a new position in shares of CureVac in the 4th quarter valued at about $158,000. Virtus ETF Advisers LLC lifted its holdings in shares of CureVac by 64.7% in the 4th quarter. Virtus ETF Advisers LLC now owns 16,018 shares of the company’s stock valued at $67,000 after buying an additional 6,295 shares during the period. Nuveen Asset Management LLC acquired a new position in shares of CureVac in the 4th quarter valued at about $354,000. Occudo Quantitative Strategies LP acquired a new position in shares of CureVac in the 4th quarter valued at about $64,000. Finally, Brevan Howard Capital Management LP purchased a new position in shares of CureVac in the 4th quarter valued at about $59,000. Institutional investors and hedge funds own 17.26% of the company’s stock.

About CureVac

(Get Free Report)

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza.

Read More

Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.